论文部分内容阅读
目的:观察聚乙二醇干扰素α-2a治疗慢性乙型肝炎的抗病毒、抗纤维化疗效。方法:100例HBe Ag阳性的慢性乙肝患者,给予聚乙二醇干扰素α-2a 180μg,皮下注射,每周1次,疗程48周。观察其治疗12周、24周、48周时血清HBs Ag定量、HBe Ag定量、ALT复常率、HBV-DNA阴转率、瞬时肝弹性测定数值。结果:患者在治疗12周、24周、48周时血清HBs Ag定量、HBe Ag定量逐渐下降,HBV-DNA阴转率增加,ALT复常率提高,瞬时肝弹性测定数值逐渐下降,各治疗节点间比较,差异均有统计学意义(P<0.05);且HBs Ag定量、HBe Ag定量与瞬时肝弹性测定之间呈正相关,相关系数分别为0.826、0.782(P<0.05)。结论:聚乙二醇干扰素α-2a在慢性乙肝患者的抗病毒、抗纤维化治疗中,疗效确定。
Objective: To observe the anti-virus and anti-fibrosis effects of pegylated interferon α-2a in the treatment of chronic hepatitis B Methods: 100 HBeAg-positive chronic hepatitis B patients were given pegylated interferon α-2a 180 μg subcutaneously once a week for 48 weeks. Observed at 12 weeks, 24 weeks, 48 weeks, serum HBsAg quantitation, HBeAg quantification, ALT normalization rate, HBV-DNA negative conversion rate, transient liver elasticity test values. Results: After treatment for 12, 24 and 48 weeks, the serum HBsAg was quantified, the quantitative of HBe Ag was gradually decreased, the HBV-DNA negative conversion rate was increased, the ALT normalization rate was increased and the value of transient liver elasticity was decreased. (P <0.05). There was a positive correlation between HBs Ag quantitation and HBe Ag quantitation and transient liver elasticity test, the correlation coefficients were 0.826,0.782 (P <0.05) respectively. Conclusion: Pegylated interferon α-2a is effective in treating antiviral and anti-fibrosis in chronic hepatitis B patients.